Evidence map›Paper›PMID 30239838›Full record

ArticleThe Journal of infectious diseases2019

Serologic Markers for Ebolavirus Among Healthcare Workers in the Democratic Republic of the Congo.

Nicole A Hoff, Patrick Mukadi, Reena H Doshi, Matthew S Bramble, Kai Lu, Adva Gadoth, Cyrus Sinai, D'Andre Spencer, Bradley P Nicholson, Russell Williams and 9 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04186000 (Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04186000 phase2completednot on this map

Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo

TypeinterventionalSponsorUniversiteit AntwerpenRan2019 to 2022Enrolled699ConditionsEbola Virus DiseaseArmsAd26.ZEBOV vaccine
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Nicole A HoffDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
Patrick MukadiInstitut National de Recherche Biomédicale, Washington, District of Columbia.
Reena H DoshiDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
Matthew S BrambleDepartment of Genetic Medicine Research, Children's Research Institute, Children's National Medical Center, Washington, District of Columbia.
Kai LuBlood Systems Research Institute, San Francisco.
Adva GadothDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
Cyrus SinaiDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
D'Andre SpencerDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
Bradley P NicholsonMolecular Epidemiology Research Laboratory, Veterans Affairs Medical Center, Durham, North Carolina.
Russell WilliamsUniversity of California, Los Angeles-DRC Research Program.
Matthias MossokoDirection de lutte contre la Maladie, Ministère de la Santé Publique.
Benoit Ilunga-KebelaDirection de lutte contre la Maladie, Ministère de la Santé Publique.
Joseph WasiswaUniversity of California, Los Angeles-DRC Research Program.
Emile Okitolonda-WemakoyEcole de Sante Publique, Université de Kinshasa, DRC.
Vivian H AlfonsoDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
Imke SteffenBlood Systems Research Institute, San Francisco.
Jean-Jacques Muyembe-TamfumInstitut National de Recherche Biomédicale, Washington, District of Columbia.
Graham SimmonsBlood Systems Research Institute, San Francisco.
Anne W RimoinDepartment of Epidemiology, Fielding School of Public Health, University of California, Los Angeles.
University of California, Los Angeles · USUniversity of California, San Francisco · USUniversity of Kinshasa · CDMinistère de la Santé Publique · BIChildren's National · USDurham VA Medical Center · US

Funding

University of California Launching Future Leaders in Global Health Research Training ProgramD43TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIG R COHEN, Sung-Jae Lee · 2017 to 2026
$14.7M
Serological prevalence of viral hemorrhagic fevers in Equatorial AfricaR21AI107420 · NIAID · VITALANT · PI SIMMONS, GRAHAM · 2014 to 2015
$438k
FIC NIH HHS D43 TW009343NIAID NIH HHS R21 AI107420
6 · The paper itself

Abstract

Healthcare settings have played a major role in propagation of Ebola virus (EBOV) outbreaks. Healthcare workers (HCWs) have elevated risk of contact with EBOV-infected patients, particularly if safety precautions are not rigorously practiced. We conducted a serosurvey to determine seroprevalence against multiple EBOV antigens among HCWs of Boende Health Zone, Democratic Republic of the Congo, the site of a 2014 EBOV outbreak. Interviews and specimens were collected from 565 consenting HCWs. Overall, 234 (41.4%) of enrolled HCWs were reactive to at least 1 EBOV protein: 159 (28.1%) were seroreactive for anti-glycoprotein immunoglobulin G (IgG), 89 (15.8%) were seroreactive for anti-nucleoprotein IgG, and 54 (9.5%) were VP40 positive. Additionally, sera from 16 (2.8%) HCWs demonstrated neutralization capacity. These data demonstrate that a significant proportion of HCWs have the ability to neutralize virus, despite never having developed Ebola virus disease symptoms, highlighting an important and poorly documented aspect of EBOV infection and progression.

Indexed as

Health PersonnelSeroepidemiologic StudiesAdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralDemocratic Republic of the CongoEbolavirusFemaleHumansImmunoglobulin GMaleMiddle AgedSurveys and QuestionnairesYoung AdultAntibodies, NeutralizingAntibodies, ViralImmunoglobulin G

Identifiers

PMID30239838
PMCPMC6350949
OpenAlexW2891943062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.